AndrÃ©s F. Muro

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7002435/publications.pdf

Version: 2024-02-01

84	3,804	147801	128289
papers	citations	31 h-index	60 g-index

86	86	86	4808
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Integrin-Î±9 Is Required for Fibronectin Matrix Assembly during Lymphatic Valve Morphogenesis. Developmental Cell, 2009, 17, 175-186.	7.0	290
2	New insights into form and function of fibronectin splice variants. Journal of Pathology, 2008, 216, 1-14.	4.5	288
3	Coupling of Transcription with Alternative Splicing. Molecular Cell, 1999, 4, 251-258.	9.7	274
4	Regulated splicing of the fibronectin EDA exon is essential for proper skin wound healing and normal lifespan. Journal of Cell Biology, 2003, 162, 149-160.	5.2	274
5	An Essential Role for Fibronectin Extra Type III Domain A in Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 638-645.	5.6	257
6	Brain-specific promoter and polyadenylation sites of the Â-adducin pre-mRNA generate an unusually long 3'-UTR. Nucleic Acids Research, 2006, 34, 243-253.	14.5	201
7	Fibronectin splice variants: Understanding their multiple roles in health and disease using engineered mouse models. IUBMB Life, 2011, 63, 538-546.	3.4	141
8	EDAâ€containing cellular fibronectin induces fibroblast differentiation through binding to Î±₄Î²₇integrin receptor and MAPK/Erk 1/2â€dependent signaling. FASEB Journal, 2010, 24, 4503-4512.	0.5	130
9	Regulation of Fibronectin EDA Exon Alternative Splicing: Possible Role of RNA Secondary Structure for Enhancer Display. Molecular and Cellular Biology, 1999, 19, 2657-2671.	2.3	123
10	RNA Folding Affects the Recruitment of SR Proteins by Mouse and Human Polypurinic Enhancer Elements in the Fibronectin EDA Exon. Molecular and Cellular Biology, 2004, 24, 1387-1400.	2.3	106
11	A Major Fraction of Fibronectin Present in the Extracellular Matrix of Tissues Is Plasma-derived. Journal of Biological Chemistry, 2007, 282, 28057-28062.	3.4	104
12	Life-Long Correction of Hyperbilirubinemia with a Neonatal Liver-Specific AAV-Mediated Gene Transfer in a Lethal Mouse Model of Criglerâ€“Najjar Syndrome. Human Gene Therapy, 2014, 25, 844-855.	2.7	74
13	Rescue of bilirubinâ€induced neonatal lethality in a mouse model of Criglerâ€Najjar syndrome type I by AAV9â€mediated gene transfer. FASEB Journal, 2012, 26, 1052-1063.	0.5	71
14	A Polar Mechanism Coordinates Different Regions of Alternative Splicing within a Single Gene. Molecular Cell, 2005, 19, 393-404.	9.7	63
15	EMILIN1/Î±9Î²1 Integrin Interaction Is Crucial in Lymphatic Valve Formation and Maintenance. Molecular and Cellular Biology, 2013, 33, 4381-4394.	2.3	62
16	Control of fibroblast fibronectin expression and alternative splicing via the PI3K/Akt/mTOR pathway. Experimental Cell Research, 2010, 316, 2644-2653.	2.6	59
17	Recipientâ€derived EDA fibronectin promotes cardiac allograft fibrosis. Journal of Pathology, 2012, 226, 609-618.	4.5	50
18	A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome. Molecular Therapy - Methods and Clinical Development, 2016, 3, 16049.	4.1	50

#	Article	IF	Citations
19	Prothrombotic Effects of Fibronectin Isoforms Containing the EDA Domain. Arteriosclerosis, Thrombosis, and Vascular Biology, 2008, 28, 296-301.	2.4	46
20	Promoterless gene targeting without nucleases rescues lethality of a Criglerâ€Najjar syndrome mouse model. EMBO Molecular Medicine, 2017, 9, 1346-1355.	6.9	46
21	Absence of regulated splicing of fibronectin EDA exon reduces atherosclerosis in mice. Atherosclerosis, 2008, 197, 534-540.	0.8	45
22	Preclinical Development of an AAV8-hUGT1A1 Vector for the Treatment of Crigler-Najjar Syndrome. Molecular Therapy - Methods and Clinical Development, 2019, 12, 157-174.	4.1	45
23	Regulation of the fibronectin EDA exon alternative splicing. Cooperative role of the exonic enhancer element and the 5â€² splicing site. FEBS Letters, 1998, 437, 137-141.	2.8	41
24	Bilirubin-Induced Oxidative Stress Leads to DNA Damage in the Cerebellum of Hyperbilirubinemic Neonatal Mice and Activates DNA Double-Strand Break Repair Pathways in Human Cells. Oxidative Medicine and Cellular Longevity, 2018, 2018, 1-11.	4.0	41
25	TDP-43 regulatesÎ²-adducin(Add2) transcript stability. RNA Biology, 2014, 11, 1280-1290.	3.1	40
26	Î²â€adducin (Add2) KO mice show synaptic plasticity, motor coordination and behavioral deficits accompanied by changes in the expression and phosphorylation levels of the Î±â€and Î³â€adducin subunits. Genes, Brain and Behavior, 2010, 9, 84-96.	2.2	39
27	Attenuation of neuro-inflammation improves survival and neurodegeneration in a mouse model of severe neonatal hyperbilirubinemia. Brain, Behavior, and Immunity, 2018, 70, 166-178.	4.1	39
28	Hypertension in Î²-Adducinâ€“Deficient Mice. Hypertension, 2000, 36, 449-453.	2.7	37
29	Age-dependent pattern of cerebellar susceptibility to bilirubin neurotoxicityin vivo. DMM Disease Models and Mechanisms, 2014, 7, 1057-68.	2.4	36
30	EDA fibronectinâ€“TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis. Journal of Experimental Medicine, 2019, 216, 587-604.	8.5	36
31	Inflammatory signature of cerebellar neurodegeneration during neonatal hyperbilirubinemia in Ugt1 -/- mouse model. Journal of Neuroinflammation, 2017, 14, 64.	7.2	34
32	Impairment of enzymatic antioxidant defenses is associated with bilirubin-induced neuronal cell death in the cerebellum of Ugt1 KO mice. Cell Death and Disease, 2015, 6, e1739-e1739.	6.3	33
33	Alternative splicing of fibronectin: a mouse model demonstrates the identity of in vitro and in vivo systems and the processing autonomy of regulated exons in adult mice. Gene, 2004, 324, 55-63.	2.2	32
34	Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases. JCI Insight, 2019, 4, .	5.0	28
35	The extra domain AÂof fibronectin is essential for allergen-induced airway fibrosis and hyperresponsiveness in mice. Journal of Allergy and Clinical Immunology, 2011, 127, 439-446.e5.	2.9	27
36	Repeated AAV-mediated gene transfer by serotype switching enables long-lasting therapeutic levels of hUgt1a1 enzyme in a mouse model of Criglerâ€“Najjar Syndrome Type I. Gene Therapy, 2017, 24, 649-660.	4.5	27

#	Article	IF	Citations
37	CPEB2, CPEB3 and CPEB4 are coordinately regulated by miRNAs recognizing conserved binding sites in paralog positions of their 3â€²-UTRs. Nucleic Acids Research, 2010, 38, 7698-7710.	14.5	25
38	The CRE-binding factor ATF-2 facilitates the occupation of the CCAAT box in the fibronectin gene promoter. FEBS Letters, 1993, 327, 25-28.	2.8	24
39	Hypertension-Linked Decrease in the Expression of Brain Î³-Adducin. Circulation Research, 2002, 91, 633-639.	4.5	22
40	Albumin administration prevents neurological damage and death in a mouse model of severe neonatal hyperbilirubinemia. Scientific Reports, 2015, 5, 16203.	3.3	22
41	Impaired motor coordination in mice lacking the EDA exon of the fibronectin gene. Behavioural Brain Research, 2005, 161, 31-38.	2.2	21
42	Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice. Thrombosis and Haemostasis, 2015, 114, 186-197.	3.4	21
43	EDA-Containing Fibronectin Increases Proliferation of Embryonic Stem Cells. PLoS ONE, 2013, 8, e80681.	2.5	21
44	Characterisation and chromosomal localisation of the rat Î±- and Î²-adducin-encoding genes. Gene, 1995, 166, 307-311.	2.2	19
45	Genomic organisation and chromosomal localisation of the gene encoding human beta adducin. Gene, 1995, 167, 313-316.	2.2	19
46	Neurospora crassacDNA clones coding for a new member of therasprotein family. FEBS Letters, 1990, 273, 103-106.	2.8	17
47	Involvement of fibronectin in the regulation of urokinase production and binding in murine mammary tumor cells. , 1999, 82, 748-753.		17
48	The erythrocyte skeletons of Î²-adducin deficient mice have altered levels of tropomyosin, tropomodulin and EcapZ. FEBS Letters, 2004, 576, 36-40.	2.8	17
49	Lack of Fibronectin Extra Domain A Alternative Splicing Exacerbates Endothelial Dysfunction in Diabetes. Scientific Reports, 2016, 6, 37965.	3.3	17
50	Advances in understanding disease mechanisms and potential treatments for Criglerâ€“Najjar syndrome. Expert Opinion on Orphan Drugs, 2018, 6, 425-439.	0.8	17
51	Expression of RGD minus fibronectin that does not form extracellular matrix fibrils is sufficient to decrease tumor metastasis. , 1998, 78, 233-241.		16
52	Beclinâ€1â€mediated activation of autophagy improves proximal and distal urea cycle disorders. EMBO Molecular Medicine, 2021, 13, e13158.	6.9	16
53	An Exonic Splicing Enhancer Offsets the Atypical GU-rich 3â€² Splice Site of Human Apolipoprotein A-II Exon 3. Journal of Biological Chemistry, 2004, 279, 39331-39339.	3.4	15
54	Experimental models assessing bilirubin neurotoxicity. Pediatric Research, 2020, 87, 17-25.	2.3	14

#	Article	IF	Citations
55	DNA sequencing by the chemical method: a 10 minute procedure for the G+A reaction. Trends in Genetics, 1993, 9, 337-338.	6.7	13
56	Binding of nuclear factors to a satellite DNA of retroviral origin with marked differences in copy number among species of the rodentCtenomys. Nucleic Acids Research, 1994, 22, 656-661.	14.5	13
57	Modulation of bilirubin neurotoxicity by the Abcb1 transporter in theUgt1-/-lethal mouse model of neonatal hyperbilirubinemia. Human Molecular Genetics, 2016, 26, ddw375.	2.9	13
58	Long-term correction of ornithine transcarbamylase deficiency in Spf-Ash mice with a translationally optimized AAV vector. Molecular Therapy - Methods and Clinical Development, 2021, 20, 169-180.	4.1	12
59	Human liver stem cells express UGT1A1 and improve phenotype of immunocompromised Crigler Najjar syndrome type I mice. Scientific Reports, 2020, 10, 887.	3.3	11
60	Generation of Ugt1-Deficient Murine Liver Cell Lines Using TALEN Technology. PLoS ONE, 2014, 9, e104816.	2.5	11
61	Regulation of the human apolipoprotein AIV gene expression in transgenic mice. FEBS Letters, 1999, 445, 45-52.	2.8	9
62	Brief Report: Alternative Splicing of Extra Domain A (EIIIA) of Fibronectin Plays a Tissue-Specific Role in Hematopoietic Homeostasis. Stem Cells, 2016, 34, 2263-2268.	3.2	9
63	A Quantitative InÂVitro Potency Assay for Adeno-Associated Virus Vectors Encoding for the UGT1A1 Transgene. Molecular Therapy - Methods and Clinical Development, 2020, 18, 250-258.	4.1	9
64	Efficacy of AAV8-hUGT1A1Âwith Rapamycin in neonatal, suckling, and juvenile rats to model treatment in pediatric CNs patients. Molecular Therapy - Methods and Clinical Development, 2021, 20, 287-297.	4.1	9
65	Unexpected Rescue of Alpha-synuclein and Multimerin1 Deletion in C57BL/6JOlaHsd Mice by Beta-adducin Knockout. Transgenic Research, 2006, 15, 255-259.	2.4	8
66	Characterization of the Distal Polyadenylation Site of the ÃŸ-Adducin (Add2) Pre-mRNA. PLoS ONE, 2013, 8, e58879.	2.5	8
67	Promoterless Gene Targeting Approach Combined to CRISPR/Cas9 Efficiently Corrects Hemophilia B Phenotype in Neonatal Mice. Frontiers in Genome Editing, 2022, 4, 785698.	5.2	8
68	Fludarabine increases nuclease-free AAV- and CRISPR/Cas9-mediated homologous recombination in mice. Nature Biotechnology, 2022, 40, 1285-1294.	17.5	8
69	Identification of 3â€² gene ends using transcriptional and genomic conservation across vertebrates. BMC Genomics, 2012, 13, 708.	2.8	5
70	Extra domain-A fibronectin is necessary for the development of nasal remodeling in chronic allergen-induced rhinitis. Annals of Allergy, Asthma and Immunology, 2013, 110, 322-327.	1.0	5
71	Structural and Functional Analysis of the cAMP Binding Domain from the Regulatory Subunit of Mucor rouxii Protein Kinase A. Archives of Biochemistry and Biophysics, 2000, 382, 173-181.	3.0	4
72	Alternatively spliced fibronectin extra domain A is required for hemangiogenic recovery upon bone marrow chemotherapy. Haematologica, 2018, 103, e42-e45.	3.5	4

#	ARTICLE	IF	CITATIONS
73	Long-distance regulation of Add2 pre-mRNA3â€²end processing. RNA Biology, 2013, 10, 516-527.	3.1	3
74	EDA Fibronectin-TLR4 Axis Sustains Megakaryocyte Expansion and Inflammation during Bone Marrow Fibrosis Progression. Blood, 2018, 132, 1781-1781.	1.4	3
75	Long-Term Effects of Biliverdin Reductase a Deficiency in Ugt1aˆ’/aˆ’ Mice: Impact on Redox Status and Metabolism. Antioxidants, 2021, 10, 2029.	5.1	3
76	Stam2 expression pattern during embryo development. Gene Expression Patterns, 2012, 12, 68-76.	0.8	2
77	Gene Therapy in Pediatric Liver Disease. , 2019, , 799-829.		2
78	158. Cryptic ATG Removal from Synthetic Introns Increase the Therapeutic Efficacy of AAV Vector Mediated Gene Transfer. Molecular Therapy, 2016, 24, S62.	8.2	1
79	Absence of fibronectin-EDA contributes to sepsis outcomes in a murine model. Atherosclerosis, 2016, 252, e179.	0.8	1
80	Extra Domain A Fibronectin Promotes Fibrotic Remodeling In Chronic Cardiac Allograft Rejection. , 2011, , .		0
81	547. Untranslated Region Optimization Increases Transgene mRNA and Protein Levels, Resulting in Enhanced Therapeutic Efficacy of AAV Vector Gene Transfer In Vivo for Crigler-Najjar Syndrome. Molecular Therapy, 2015, 23, S219-S220.	8.2	0
82	688. AAV8-Mediated Liver Gene Targeting Without Nucleases Rescues Lethality in a Mouse Model of the Crigler-Najjar Syndrome. Molecular Therapy, 2015, 23, S274.	8.2	0
83	704. Long-Term Correction of Crigler-Najjar Syndrome and Scale-Up Production of an Optimized AAV8 Vector Expressing the UGT1A1 Transgene. Molecular Therapy, 2015, 23, S280-S281.	8.2	0
84	Low efficacy of recombinant SV40 in Ugt1a1-/- mice with severe inherited hyperbilirubinemia. PLoS ONE, 2021, 16, e0250605.	2.5	0